Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Are you planning to get a baby? Protect your child by screening for hereditary disorders that you may pass to them ...

According to the U.N. refugee agency, more than 470,000 people — around 70% of them Syrian — have crossed the border since ...

VIJAYAWADA: Chief Minister N Chandrababu Naidu, came across a woman who turned emotional when Eluru police recovered 251 ...

RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...

Its first approved product, Casgevy, was developed in collaboration with narrow-moat Vertex Pharmaceuticals to treat transfusion-dependent beta-thalassemia (TDT) and sickle-cell disease (SCD). Crispr ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

Agios Pharmaceuticals (AGIO) announced that new data on mitapivat and tebapivat, AG-946, the company’s PK activators, will be featured in ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

New Delhi: Thalassemia patients at Delhi’s government hospitals are grappling with a “double whammy” amid a shortage of Desferal (deferoxamine mesylate) and a looming 50 percent price hike for the ...